In lung cancer treatment, the initial clinical response is satisfactory but eventually resistance is developed due the mutation in EGFR (T790M) (Pao et al., 2005), MET gene amplification, and the activation of NF- κB and TGF-β (Engelman et al., 2007; Bivona et al., 2011; Huang et al., 2012). Here, EGFR is linked to lung cancer.